ModernVivo: Funding, Investors & Team (Sep 2026)
New drugs fail in human clinical trials 90% of the time. These failures can be traced directly back to the consistent inability of preclinical animal studies to predict clinical success. Yet the design process for preclinical animal studies has remained largely unchanged for decades; scientists read a tiny fraction of published literature and write their experimental protocols in 2-4 weeks. This time-consuming, tedious process is not only a major pain point for in-vivo scientists but leads to substantial experimental design flaws, resulting in unreliable data with which billion-dollar decisions are made. Scientists we’ve spoken to repeatedly express their struggle with the overwhelming amount of preclinical information they need to sift through in order to design experiments. At ModernVivo, we are revolutionizing this antiquated process by equipping scientists with tools that enable them to write in-vivo protocols more effectively. Our technology empowers scientists to streamline their work, accelerating drug development timelines.
ModernVivo has raised $20k across 1 funding round on record, the most recent an undisclosed round of $20k announced in Aug 2023.
That round is below the $5.5M median round size for Artificial Intelligence companies tracked on FundedIQ over the last two years.
ModernVivo Company Profile and Key Stats
Latest funding round on record: Aug 2023.
ModernVivo Funding Rounds
ModernVivo Founders and Leadership Team
Contact details for the ModernVivo team: 1 of 1 has an email address on file.
Start 14-day free trial →ModernVivo Funding Compared to Other Artificial Intelligence Startups
ModernVivo's latest round of $20k is below the median round in Artificial Intelligence. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ModernVivo in Artificial Intelligence and Ann Arbor
Companies Similar to ModernVivo
Socure is a predictive analytics platform for digital identity verification of consumers. Socure's predictive…
Instinct is an artificial intelligence startup developing AI technology.
Significant gives vehicle-mounted PC vision innovation that distinguishes visual deformities in network…
Cloverleaf AI exists to help you fill your pipeline with high-quality SLED leads. Tell us what you deliver,…
Emerald AI develops software and platforms that manage and coordinate energy use for artificial intelligence…
Gatik, a new company, is creating technology for self-driving trucks that are used for short-distance…
Generalist AI develops AI and robotics technologies focused on enabling robots to perform physical tasks in…
Quintessent is a start-up in Santa Barbara that specializes in bringing quantum dot-based lasers and photonic…
Contact: Cardiosense is building a physiological waveform data platform that leverages novel multi-modal…
Thunder is a Cloud computing to democratize access to GPUs and solve the ongoing GPU shortage. Decentralized…
Deepgram helps enterprises unlock the potential of their audio data with custom trained speech recognition…
ModernVivo Funding FAQs
What does ModernVivo do?
New drugs fail in human clinical trials 90% of the time. These failures can be traced directly back to the consistent inability of preclinical animal studies to predict clinical success. Yet the design process for preclinical animal studies has remained largely unchanged for decades; scientists read a tiny fraction of published literature and write their experimental protocols in 2-4 weeks. This time-consuming, tedious process is not only a major pain point for in-vivo scientists but leads to substantial experimental design flaws, resulting in unreliable data with which billion-dollar decisions are made. Scientists we’ve spoken to repeatedly express their struggle with the overwhelming amount of preclinical information they need to sift through in order to design experiments. At ModernVivo, we are revolutionizing this antiquated process by equipping scientists with tools that enable them to write in-vivo protocols more effectively. Our technology empowers scientists to streamline their work, accelerating drug development timelines.
How much funding has ModernVivo raised?
ModernVivo has raised $20k across 1 round on record. The most recent is an undisclosed round of $20k announced in Aug 2023.
When did ModernVivo last raise funding?
ModernVivo's most recent funding round on record is an undisclosed round of $20k, announced in Aug 2023.
Who is the CEO of ModernVivo?
Ian Levine is listed as CEO at ModernVivo.
Where is ModernVivo headquartered?
ModernVivo is based in Ann Arbor, Michigan, United States.
How many employees does ModernVivo have?
ModernVivo is in the 1-10 employee band.
How does ModernVivo's funding compare to other Artificial Intelligence startups?
ModernVivo's latest round of $20k is below the $5.5M median round size for Artificial Intelligence companies on FundedIQ across 7,233 tracked companies over the last two years.
About FundedIQ's ModernVivo Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ModernVivo is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.